Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus less than 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
Our life sciences industry partner, BioUTAH, published a nice article on their website that highlights some of our recent accomplishments. Follow the link below to read it and learn more about BioUTAH. BioUtah is an independent, non-profit 501(c)(6) trade association serving the life sciences community
IONIQ Sciences announces institutional offering Salt Lake City, UT, May 28, 2020 – IONIQ Sciences Inc. (“IONIQ Sciences” or the “Company”), announced it is initiating an institutional private equity offering on the heels of receiving ‘Breakthrough Device Designation’ from the U.S. FDA for its lung
Salt Lake City, UT, May 27, 2020 – IONIQ Sciences Inc. (“IONIQ Sciences” or the “Company”), which is changing the cancer landscape with a modern multi-cancer screening technology using its non-invasive Electrical Impedance Analytics (EIA) technology and a proprietary algorithm, announced it is changing its
